Search results

{{r|New drug application}}

...pprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2008.<ref>{{FDA-Drug_Details|065379}}</ref>

...pprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2009.<ref>{{FDA-Drug_Details|078560}}</ref>

...owDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) in 2002.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

...owDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) in 1993.<ref>{{FDA-Drug_Details|020151}}</ref> A generic version wa

...pprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) in 2003.<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda

=== Abbreviated New Drug Application === ...ications/AbbreviatedNewDrugApplicationANDAGenerics/default.htm Abbreviated New Drug Application] (or "ANDA") with the [[Food and Drug Administration]] (FDA) and seeks to d

...pprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ Abbreviated New Drug Application] (ANDA) on July 29, 1999.<ref>{{FDA-Drug_Details|040353}}</ref>

...ability and bioavailablility, and suggested packaging and labeling, as a [[new drug application]] (NDA) to the FDA. The NDA is then reviewed by teams of FDA employees, inc ...per study and testing. The drug industry must pay "user fees" with every [[new drug application]]. A drug is given "fast-track" status if it meets a medical need not curre

...owDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) by the FDA in 1987.<ref>[http://www.accessdata.fda.gov/scripts/cder/

...owDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/ New Drug Application] (NDA) by the FDA in 1987.<ref>[http://www.accessdata.fda.gov/scripts/cder/

Trials of potential treatments, for ethical reasons, tend to involve [[New Drug Application|multiple stages]], starting with small safety tests of the drug or other th ...onsent]] for participation in a trial. In the United States, there is an [[New drug application| approval procedure]] for clinical trials in human subjects, whether for re

...cy authorization for the use of intravenous peramavir, which had been in [[New Drug Application|Phase III clinical trials]]. <ref name=FDA-EUA-par>{{citation

Trials of potential treatments, for ethical reasons, tend to involve [[New Drug Application|multiple stages]], starting with small safety tests of the drug or other th ...onsent]] for participation in a trial. In the United States, there is an [[New drug application| approval procedure]] for clinical trials in human subjects, whether for re